Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice

HIV Clinical Trials

Volumn 10, Issue 3, 2009, Pages 129-134

  Santos, José Ramón ^a,b   Moltó, José ^a,b   Llibre, Josep Maria ^a   Pérez, Nuria ^a,c   Capitán, Mari Carmen ^a   Miranda, Cristina ^a   Clotet, Bonaventura ^a,d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^d IrsiCaixa Foundation   (Spain)

Author keywords

Lamivudive abacavir co formulated; Simplification strategy; Unboosted ATV

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; CHOLESTEROL; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; RITONAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONVALESCENCE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER TOXICITY; LONG TERM CARE; LYMPHOCYTE COUNT; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 69249131697     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1003-129     Document Type: Article

References (16)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodefi ciency virus infection. N Engl J Med. 1998;338(13):853-860.
2. Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother. 2007;60(6):1195-1205.
3. King JR, Wynn H, Brundage R, Acosta EP. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet. 2004;43(5):291-310.
4. FDA. CDER. Reyataz (online). Available at: http://www. fda.gov/cder/foi/label/2006/021567s007lbl.pdf. Accessed July 2008.
5. Squires K, Lazzarin A, Gatell J, et al. Comparison of oncedaily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36(5):1011-1019.
6. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine in ARV-naive HIV- 1-infected subjects: the CASTLE study, 48-week results. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA. Abstract 37.
7. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2008;47(2):161-167.
8. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44(11):1484-1492.
9. Kivexa, INN-abacavir/lamivudine (online). Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ Kivexa/H-581-PI-es.pdf. Accessed July 2008.
10. Gonzalez de Requena D, Bonora S, Canta F, et al. Atazanavir Ctrough is associated with efficacy and safety: defi nition of therapeutic range. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, MA. Abstract 645.
11. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579.
12. Poirier JM, Guiard-Schmid J, Meynard J, et al. Atazanavir (ATV) plasma concentrations in HIV-infected patients treated with 400 mg ATV or ritonavir boosted ATV (300/100 mg) qd in clinical practice. In: Program and abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006; Lisbon. Abstract 11.
13. Moltó J, Santos JR, Valle M, et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit. 2007;29(5):648-651.
14. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin. 2005;21(10):1683-1692.
15. Fulco PP, Vora UB, Bearman GM. Acid suppressive therapy and the effects on protease inhibitors (CE). Ann Pharmacother. 2006;40 (11):1974-1983.
16. Bertz R, Wang Y, Manhke L, et al. Assessment of pharmacokinetic/ pharmacodynamic relationships through 48 weeks from a study in HIV+ ARV-naive subjects receiving antiretroviral regimens containing atazanavir 400 mg or atazanavir/ritonavir 300/100 mg once daily. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles. Abstract 565.